Mironid Limited is an innovative new drug discovery company that develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. This allows us to access multiple therapeutic areas for exploitation. Our current drug discovery pipeline is aimed at developing novel treatments for degenerative kidney diseases, chronic inflammatory diseases and cancer.
New Product & Tech activity — 1 fresh signal just appeared.
The order this company entered each market — oldest to newest
Mironid Raises $46M Series B
Linode · Cedar Knolls
Sign up to see the full signal feed
How Mironid® Limited's international expansion compares to its competitors
Mironid® LimitedYouBars show relative size across the companies compared.
5 metrics| Company | Markets | New markets | Momentum | Activity | Expansion score |
|---|---|---|---|---|---|
 Mironid® LimitedYou | 1 | 1 | +100% | 2 | 59 |
Not hiring right now
Sign up to track this company and get alerted the moment something changes.
7 technologies detected across the stack.
No active campaigns
Sign up to track this company and get alerted the moment something changes.
1 mention in the last 90 days.
Glasgow-based Mironid raised $46 million in Series B funding to advance clinical development of small molecule therapeutics for ADPKD, a hereditary kidney disease affecting 12 million worldwide.
Unlock verified emails & direct dials
Free · No credit card needed
Quick answers about Mironid® Limited's business, markets, and growth signals.
“We reach accounts the week they land in-market — not the quarter after.”
Book a walkthrough of the movement map with our team.
Pubrio turns expansion signals across 200+ markets into one live graph, so revenue teams see which companies are entering new markets, and act on the timing.
© 2026 Pubrio. All rights reserved.
